Anti Scl-70 Test at Lahore PCR Lab

Anti Scl-70 Test at Lahore PCR Lab

Systemic sclerosis, commonly referred to as scleroderma, is a complex, multi-system autoimmune disorder characterized by tissue fibrosis, vascular alterations, and the production of specific autoantibodies. Among these immunological markers, the Anti-Scl-70 antibody, also known as the anti-topoisomerase I antibody, serves as a primary diagnostic and prognostic tool. At Lahore PCR Lab in Lahore, Pakistan, we offer state-of-the-art immunological testing to detect these autoantibodies with high sensitivity and specificity. The target antigen of this test is DNA topoisomerase I, an essential nuclear enzyme responsible for relieving torsional strain during DNA replication, transcription, and recombination. When the immune system mistakenly targets this enzyme, it produces Anti-Scl-70 autoantibodies, which can be detected in the patient’s blood serum.

This test is highly specific (nearly 95% to 100%) for systemic sclerosis, particularly the diffuse cutaneous subtype (dcSSc). Diffuse cutaneous systemic sclerosis is associated with rapid skin thickening, extensive cutaneous involvement, and a significantly higher risk of early visceral organ involvement, such as interstitial lung disease (ILD), myocardial fibrosis, and renal complications. Understanding the presence of these antibodies is crucial for rheumatologists and physicians to establish an early diagnosis, risk-stratify patients, and initiate targeted therapeutic interventions to mitigate progressive organ damage. Lahore PCR Lab utilizes advanced diagnostic platforms to ensure that patients in Lahore and surrounding regions receive highly accurate, reliable, and timely results to guide their clinical management.

Clinical Procedure: What to Expect

Patient Preparation

To ensure the accuracy of the Anti Scl-70 test and a smooth sample collection process, patients are advised to follow these preparation guidelines:

• No Fasting Required: Fasting is not strictly necessary for the Anti Scl-70 blood test. Patients can eat and drink normally before the procedure unless otherwise instructed by their physician for concurrent tests.
• Medication Disclosure: Patients must inform their healthcare provider and the laboratory staff about all current medications, including immunosuppressants, corticosteroids, and biologics, as these therapies can potentially influence overall immune profiles and antibody levels.
• Hydration: Drinking an adequate amount of water before the test is highly recommended, as proper hydration makes venipuncture easier by expanding blood volume and making veins more accessible.
• Avoid Strenuous Activity: It is advisable to avoid heavy physical exertion immediately before the blood draw to maintain baseline physiological conditions.

During the Procedure

The sample collection process at Lahore PCR Lab is designed to be quick, safe, and minimally invasive, adhering to strict international clinical standards:

• Patient Identification and Verification: The phlebotomist will first verify the patient’s identity and confirm the specific test requested to ensure absolute accuracy in labeling and tracking.
• Venipuncture Site Selection: The patient is seated comfortably, and the phlebotomist inspects the arm to locate a suitable vein, typically the median cubital vein in the antecubital fossa (the bend of the elbow).
• Aseptic Preparation: The selected site is thoroughly cleansed with an antiseptic swab (usually 70% isopropyl alcohol) to prevent any microbial contamination of the sample or the puncture site.
• Blood Collection: A sterile, single-use needle is gently inserted into the vein. Blood is drawn into a serum separator tube (SST) or a plain red-top tube. The collection process generally takes less than one minute.
• Post-Puncture Care: Once the required volume of blood is collected, the needle is carefully removed, and immediate pressure is applied to the site with a sterile cotton ball or gauze pad to promote hemostasis. A small adhesive bandage is then applied.
• Specimen Processing: The collected blood sample is allowed to clot naturally at room temperature. It is then centrifuged to separate the serum from the cellular components. The isolated serum is analyzed using advanced Enzyme-Linked Immunosorbent Assay (ELISA) or Chemiluminescence Immunoassay (CLIA) technology.

When is an Anti Scl-70 Test Performed?

Investigating Suspected Systemic Sclerosis (Scleroderma)

Physicians request the Anti Scl-70 test when a patient presents with clinical signs suggestive of systemic sclerosis. These signs may include skin tightening, particularly on the fingers (sclerodactyly), hands, and face, as well as joint pain, stiffness, and unexplained swelling. The test helps confirm the diagnosis of systemic sclerosis and distinguishes it from other autoimmune diseases that present with overlapping symptoms.

Evaluating Raynaud’s Phenomenon

Raynaud’s phenomenon is a condition characterized by exaggerated vascular spasms in response to cold temperatures or emotional stress, causing the fingers and toes to turn white, blue, and then red. While primary Raynaud’s is benign, secondary Raynaud’s can be the first manifestation of systemic sclerosis. Testing for Anti Scl-70 in patients with severe or newly onset Raynaud’s helps identify those at high risk of transitioning to systemic sclerosis.

Assessing Progressive Skin Thickening

Rapidly progressive skin thickening that extends proximal to the elbows or knees is a hallmark of diffuse cutaneous systemic sclerosis. When patients exhibit these dermatological changes, the Anti Scl-70 test is critical. Detecting these antibodies helps confirm the diffuse subtype, allowing clinicians to anticipate potential systemic complications and implement aggressive monitoring protocols.

Monitoring Interstitial Lung Disease (ILD) Risk

Interstitial lung disease is one of the most serious and potentially life-threatening complications of systemic sclerosis. There is a strong clinical association between the presence of Anti Scl-70 antibodies and the development of progressive pulmonary fibrosis. Identifying these antibodies early prompts physicians to perform baseline and serial high-resolution computed tomography (HRCT) scans of the chest and pulmonary function tests (PFTs).

Differentiating Connective Tissue Diseases

Autoimmune diseases often present with overlapping clinical features, making accurate diagnosis challenging. Patients may exhibit symptoms common to systemic lupus erythematosus (SLE), rheumatoid arthritis, polymyositis, and systemic sclerosis—a scenario often referred to as mixed or undifferentiated connective tissue disease. The Anti Scl-70 test provides high specificity, helping clinicians differentiate systemic sclerosis from other rheumatological conditions.

What Does an Anti Scl-70 Test Detect?

The Anti Scl-70 test is designed to identify and quantify specific autoantibodies in the blood. Here are the key clinical findings, interpretations, and pathological correlations associated with this diagnostic test:

• Presence of Anti-Topoisomerase I Antibodies: Detects the specific IgG autoantibodies directed against the 70 kDa fragment of the DNA topoisomerase I enzyme.
• High Specificity for Systemic Sclerosis: A positive result is highly specific (95% to 100%) for systemic sclerosis, meaning false positives are extremely rare in healthy individuals.
• Association with Diffuse Cutaneous Subtype: Strongly correlates with the diffuse cutaneous form of systemic sclerosis, characterized by widespread skin involvement.
• Predictor of Pulmonary Fibrosis: Serves as a significant risk marker for the development of severe, progressive interstitial lung disease (ILD).
• Correlation with Severe Skin Involvement: Associated with higher modified Rodnan skin scores, indicating more extensive and rapid skin thickening.
• Risk of Myocardial Fibrosis: Indicates a potential risk for cardiac complications, including myocardial fibrosis, conduction abnormalities, and arrhythmias.
• Peripheral Vascular Disease: Associated with severe digital vasculopathy, which can lead to painful digital ulcers and tissue necrosis.
• Low Association with Limited Scleroderma: Patients with limited cutaneous systemic sclerosis (lcSSc) are typically negative for Anti Scl-70 and positive for anti-centromere antibodies.
• Prognostic Indicator: Helps clinicians identify patients who may experience a more aggressive and rapidly progressive disease course.
• Diagnostic Confirmation: Provides essential serological evidence to satisfy the ACR/EULAR classification criteria for systemic sclerosis.
• Negative Result Interpretation: A negative result indicates that Anti Scl-70 antibodies were not detected, but it does not entirely rule out systemic sclerosis, as only 20% to 40% of patients with the condition test positive.
• Absence of Cross-Reactivity: Generally does not cross-react with other common autoantibodies like anti-centromere or anti-RNA polymerase III.
• Nucleolar/Homogeneous ANA Pattern: Often corresponds with specific immunofluorescence patterns on an Antinuclear Antibody (ANA) screen.
• Risk of Gastrointestinal Dysmotility: May correlate with severe esophageal and gastrointestinal involvement, leading to dysphagia and reflux.
• Association with Joint and Muscle Involvement: Positive patients often experience significant arthralgias, joint contractures, and inflammatory myopathy.
• Atypical Presentations: Can occasionally be detected in patients with overlap syndromes, such as scleromyositis.
• Antibody Stability: Unlike some other autoimmune markers, Anti Scl-70 levels do not fluctuate significantly with disease activity, meaning serial testing to monitor treatment response is generally not clinically useful.
• Assistance in Early Intervention: Early detection allows for the prompt initiation of immunosuppressive therapy (e.g., mycophenolate mofetil or cyclophosphamide) to preserve organ function.
• Evaluation of Subclinical Disease: Helps identify systemic involvement in patients who currently only exhibit mild symptoms like Raynaud’s phenomenon.
• Differentiating Primary vs. Secondary Raynaud’s: A positive test strongly points to secondary Raynaud’s associated with an underlying connective tissue disease.

Turnaround Time and Report Access at Lahore PCR Lab

At Lahore PCR Lab, we understand that waiting for diagnostic results can be an anxious time for patients and their families. Therefore, we utilize fully automated, high-throughput immunoassay systems to ensure both maximum accuracy and rapid processing. The turnaround time for the Anti Scl-70 test is typically 24 to 48 hours from the time of sample collection.

To enhance patient convenience, Lahore PCR Lab offers multiple secure methods to access diagnostic reports. Once the report is verified by our consultant pathologist, patients receive an automated SMS notification containing a direct link to download their report in PDF format. Additionally, reports can be accessed securely through the official Lahore PCR Lab online portal by entering the unique patient registration credentials. For those who prefer physical copies, printed reports can be collected directly from our main facility or designated collection centers across Lahore.

Anti Scl-70 Findings Overview

The following table outlines the clinical parameters evaluated during the Anti Scl-70 test and their corresponding normal and abnormal implications:

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Anti-Scl-70 Antibody Level	Negative (typically < 1.0 U or within lab-specific reference range)	Positive (elevated levels indicating presence of anti-topoisomerase I antibodies)
ANA Pattern Correlation	Negative or unrelated pattern	Atypical nucleolar or homogeneous immunofluorescence pattern on HEp-2 cells
Skin Involvement (Clinical Correlation)	Normal skin turgor and elasticity	Sclerodactyly, proximal skin thickening, high modified Rodnan skin score
Pulmonary Function (PFT Correlation)	Normal forced vital capacity (FVC) and DLCO	Decreased FVC and DLCO, indicating restrictive lung disease/pulmonary fibrosis
Chest Imaging (HRCT Correlation)	Clear lung parenchyma, no fibrotic changes	Ground-glass opacities, traction bronchiectasis, honeycombing (interstitial lung disease)
Vascular Response (Raynaud’s)	Normal peripheral circulation	Severe digital vasospasm, prolonged capillary refill, digital ulcers
Esophageal Function	Normal peristalsis and lower esophageal sphincter tone	Esophageal dysmotility, severe gastroesophageal reflux, dysphagia

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Lahore PCR Lab for Anti Scl-70?

• Experienced Healthcare Professionals: Our laboratory is staffed by highly qualified pathologists, immunologists, and technologists dedicated to diagnostic excellence.
• Patient-Focused Care: We prioritize patient comfort, safety, and confidentiality throughout the testing process.
• Quality Diagnostic Services: Lahore PCR Lab adheres to strict internal and external quality control protocols to ensure reliable test results.
• Professional Reporting: Our reports are comprehensive, clear, and structured to assist clinicians in making accurate diagnostic decisions.
• Modern Diagnostic Approach: We utilize advanced automated immunoassay platforms for precise antibody detection.
• Comfortable Environment: Our collection centers in Lahore are designed to provide a clean, welcoming, and stress-free experience for patients.
• Convenient Location: Easily accessible main facility and collection points across Lahore, Pakistan.
• Commitment to Accurate Diagnosis: We understand the critical nature of autoimmune diagnostics and are committed to delivering results you can trust.